Nushama
Nushama operates a three-clinic psychedelic wellness network delivering medically supervised IV ketamine, FDA-approved Spravato, accelerated TMS, and NAD+ therapy for treatment-resistant depression, PTSD, anxiety, and trauma in the New York metro area and South Florida.
- Company typePrivate
- Founded2021
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Nushama does
Nushama is a privately held, for-profit operator of medically supervised psychedelic wellness clinics founded in 2021 and headquartered at 515 Madison Avenue, New York, with 11–50 employees (per LinkedIn). It runs a three-location network — Midtown Manhattan, Rockland County NY, and Aventura FL — delivering IV ketamine infusions, FDA-approved Spravato (esketamine), accelerated One-Day TMS, NAD+ IV therapy, and Niagen (NR) therapy to patients with treatment-resistant depression, anxiety, PTSD, OCD, eating disorders, postpartum depression, migraines, suicidal ideation, palliative care needs, and alcohol use disorder. Treatment protocols follow a structured arc — psychiatric and medical intake, preparation sessions, six IV ketamine sessions over three to six weeks (or Spravato induction twice weekly for four weeks with weekly maintenance), continuous vital-sign monitoring, and integration coaching — augmented by a published 2025 real-world PTSD outcomes study (75.21% clinically meaningful improvement, 61.54% full remission) and a KARE partnership with Awakn Life Sciences for alcohol use disorder.
The revenue model is hybrid professional-services and subscription/recurring: IV ketamine and TMS are predominantly out-of-pocket session fees (typically six-session protocols); Spravato is in-network with Oxford, UnitedHealthcare, Cigna, Aetna, and Medicare; NAD+ and Niagen are per-session or bundled add-ons; financing is available via CareCredit and HSA/FSA. Pricing accessibility is extended through the Hero's Journey scholarship program (a 25% discount for first responders and veterans) and monthly financial-based scholarships. Go-to-market combines direct-to-consumer intake, healthcare provider referrals via a dedicated for-providers portal, and community-led growth (bi-weekly integration circles, PR coverage in the NYT, WSJ, Elle, Good Morning America, New York Magazine, and Forbes). Operations are supported by HIPAA-compliant privacy protocols, FDA REMS certification for Spravato, and DEA-licensed dosing oversight led by Chief Medical Officer Dr. Steven Radowitz, alongside co-founders Jay Godfrey and Richard Meloff.
Nushama firmographics
Firmographics- Name
- Nushama
- Legal name
- Nushama
- Website
- https://nushama.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nushama operates a three-clinic psychedelic wellness network delivering medically supervised IV ketamine, FDA-approved Spravato, accelerated TMS, and NAD+ therapy for treatment-resistant depression, PTSD, anxiety, and trauma in the New York metro area and South Florida.
- Ownership category
- akta.pro rank
Nushama industry classification
Industry- Product category
- Ketamine Therapy Clinics
- NAICS
- Outpatient Mental Health and Substance Abuse Centers (621420)
- SIC
- Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Mental Health Counseling & Psychotherapy Services (EDALAFAB)
- akta.pro secondary industry
- Substance Use Recovery & Harm Reduction Support Services (BPAGAEAO)
Keywords
Where Nushama is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Nushama business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain, Technology or R&D, Others
Revenue model
- IV Ketamine Infusions: Intravenous ketamine therapy administered in a clinic setting. Typically an out-of-pocket expense, though superbills can be provided for potential out-of-network insurance reimbursement. Six-session protocols generate recurring service revenue per patient.
- Spravato (Esketamine) Treatment: FDA-approved esketamine nasal spray for treatment-resistant depression and MDD with acute suicidal ideation. Covered by in-network insurance plans including Oxford, UnitedHealthcare, Cigna, Aetna, and Medicare. Induction phase requires twice-weekly sessions for four weeks, transitioning to weekly maintenance.
- One-Day TMS: Accelerated transcranial magnetic stimulation (TMS) services compressing typical six-week treatment into accelerated protocols for time-constrained patients. Revenue generated per session.
- NAD+ and Niagen Therapy: Cellular support therapies offered as complementary treatments to ketamine, potentially billed per session or as part of bundled treatment protocols.
- CareCredit Financing: Third-party patient financing through CareCredit for out-of-pocket treatments, enabling payment plans for patients who cannot afford full upfront costs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Hero's Journey Program — 25% discount for first responders and veterans |
| Subscription | Monthly | Integration Circles — ongoing support included |
| One time/ perpetual license | Pay-as-you-go | Cancellation Policy — Journey appointments |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
Nushama product offering
Product offeringCore offering
Nushama operates a network of medically supervised psychedelic wellness clinics that administer intravenous (IV) ketamine infusions and Spravato (esketamine) nasal spray as primary treatments, supported by accelerated one-day transcranial magnetic stimulation (TMS), NAD+ IV therapy, and NIAGEN (NR) supplementation. Treatments target treatment-resistant depression, PTSD, anxiety, OCD, eating disorders, suicidal ideation, postpartum depression, migraines, burnout, palliative care, and alcohol use disorder (via the KARE protocol under partnership with Awakn Life Sciences). Services are delivered across three physical clinic locations in Manhattan, Rockland County (NY), and Aventura (FL), with psychiatric intake, continuous medical monitoring, preparation sessions, six-session IV ketamine protocols over three to six weeks, and bi-weekly integration circles forming the standard treatment arc.
Product overview
Nushama is a network of medically-supervised psychedelic wellness clinics offering ketamine-assisted therapy for mental health conditions. The core offering consists of IV Ketamine Infusions and Spravato (FDA-approved esketamine nasal spray) for conditions including treatment-resistant depression, anxiety, PTSD, and trauma. Adjacent services include One-Day TMS (accelerated transcranial magnetic stimulation), NAD+ Therapy, and NIAGEN (NR) Therapy for cellular support. Treatment protocols include preparation sessions, six IV ketamine sessions over three to six weeks, medical monitoring, and integration support. Financial access programs include the Hero's Journey 25% discount for first responders and veterans, and monthly financial-based scholarships. The company operates three locations in New York City, Rockland County, and Aventura, Florida.
Differentiator
Problem solved
Functional benefit
Brands
- Hero's Journey Program: Scholarship program offering 25% discount for first responders and veterans on all ketamine therapy services
Products and services
- Ketamine Infusions Intravenous ketamine infusions administered in a medically supervised clinical setting for treatment-resistant depression, anxiety, PTSD, OCD, eating disorders, suicidal ideation, postpartum depression, migraines, burnout, and other mood disorders; delivered as a six-session protocol over three to six weeks with preparation, continuous vital monitoring, and integration support. Typically paid out-of-pocket with superbills available for potential out-of-network insurance reimbursement.
- Spravato (Esketamine) Treatment FDA-approved esketamine nasal spray for treatment-resistant depression and major depressive disorder with acute suicidal ideation, administered under FDA REMS supervision with two-hour post-administration observation. Induction phase requires twice-weekly sessions for four weeks, transitioning to weekly maintenance, and is covered in-network by Oxford, UnitedHealthcare, Cigna, Aetna, and Medicare.
- One-Day TMS (Accelerated Transcranial Magnetic Stimulation) Accelerated transcranial magnetic stimulation protocol that compresses the typical multi-week TMS course into a single-day treatment for time-constrained patients such as executives and busy professionals, delivered as a complement or alternative to ketamine for rapid depression relief.
- NAD+ IV Therapy Intravenous nicotinamide adenine dinucleotide (NAD+) infusions used to support cellular energy, neural recovery, and physical rehabilitation, offered as a complement to ketamine treatment or as a standalone cellular-recovery and longevity service.
- NIAGEN (NR) Therapy Nicotinamide Riboside (Niagen/NR) supplementation therapy delivered to support cellular repair, mitochondrial function, and to complement the neuroplastic effects of ketamine treatment.
- Hero's Journey Program Financial-assistance access program providing a 25% discount on all Nushama services for active-duty military, veterans, police officers, fire department members, EMT workers, nurses, and teachers, supporting evidence-led psychedelic therapy access for these populations.
Quantifiable outcome
- 70-90% response rate for ketamine infusion vs. 30-60% for standard antidepressants
- +4 more outcomes
Companies that use Nushama
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles5 records
Nushama technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature4 records
Nushama partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Awakn Life SciencescoreNushama partnered with Awakn Life Sciences to offer the KARE (Ketamine-Assisted Rehabilitation and Enhancement) protocol for treating alcohol use disorder. The protocol demonstrated 86% efficacy for abstinence after six months in clinical trials — an unprecedented clinical study result. This partnership extends Nushama's evidence-based treatment portfolio with a rigorously studied psychedelic therapy protocol for addiction.
- Rater8minorNushama uses Rater8 for member reviews and testimonials, displaying review links and ratings from verified patients on team member profile pages (Dr. Steven Radowitz, Dr. Robert Glatter, Dr. Mark Braunstein). Review links are prominently displayed on the website to build credibility and social proof.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Nushama competitors and assessment
Company assessmentBroad incumbents
- Spravato (Janssen / Johnson & Johnson): Janssen's Spravato (esketamine) is the FDA-approved nasal spray version of ketamine that Nushama also administers under REMS. As the pharmaceutical incumbent, Spravato defines the regulatory and reimbursement landscape within which Nushama operates its IV ketamine and esketamine services.
- Compass Pathways: Compass Pathways is a clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Broader psychedelic therapy incumbent that competes for the same patient population and share-of-mind in psychedelic-assisted mental health treatment.
Regional players
- Restore Hyper Wellness: Restore Hyper Wellness operates a national franchise of wellness centers offering IV therapy, NAD+, cryotherapy, and other recovery modalities. Comparable in NAD+ and longevity-adjacent service offerings and franchise-style clinic delivery, though Restore focuses on wellness more than psychiatric care.
Direct peers
- Field Trip Health: Field Trip Health was a publicly listed psychedelic therapy clinic network offering ketamine-assisted psychotherapy in premium locations across North America. Closest historical direct peer to Nushama in clinic model, target patient, and therapy modality.
- Mindbloom: Mindbloom is a leading at-home ketamine therapy provider offering guided psychedelic treatment via telehealth and remote clinician supervision. Direct competitor for ketamine-treated mood disorders, competing for the same patient demographic with a different delivery model.
- Better U (formerly known as Keta Medical Center): Better U operates ketamine therapy clinics offering supervised IV ketamine treatments for mood disorders, anxiety, and PTSD in a clinical setting. Direct peer in outpatient ketamine clinic model targeting treatment-resistant populations.
- Ketamine Clinics of Los Angeles (KCLA): KCLA is one of the oldest and largest ketamine-only specialty outpatient clinics in the U.S., offering IV ketamine protocols for depression, PTSD, and chronic pain. Direct peer in clinic-based ketamine therapy for treatment-resistant mental health conditions.
- Actify Neurotherapies: Actify operates a national network of clinics offering ketamine infusion therapy combined with TMS and other neurotherapies for treatment-resistant depression. Closely comparable to Nushama in multi-modality brain-stimulation approach and outpatient clinic delivery.
Others
- Awakn Life Sciences: Awakn Life Sciences is a clinical-stage psychedelics company whose KARE protocol for alcohol use disorder Nushama licenses and delivers clinically. Direct partnership counterparty and adjacent specialty psychedelic therapeutics developer.
Emerging players
- Innerwell: Innerwell is a virtual psychiatry and ketamine-assisted therapy platform combining at-home ketamine treatment with integrative psychotherapy. Emerging competitor overlapping with Nushama on integration support and treatment-resistant mood disorders but delivered remotely.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Nushama social profiles
Digital presenceNushama compliance and trust
Trust signalCompliance2 records
Nushama financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nushama leadership team
Management profileNumber of profiles
Profiles5 records
Nushama funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nushama M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nushama
What does Nushama do?
Nushama operates a network of medically supervised psychedelic wellness clinics that administer intravenous (IV) ketamine infusions and Spravato (esketamine) nasal spray as primary treatments, supported by accelerated one-day transcranial magnetic stimulation (TMS), NAD+ IV therapy, and NIAGEN (NR) supplementation. Treatments target treatment-resistant depression, PTSD, anxiety, OCD, eating disorders, suicidal ideation, postpartum depression, migraines, burnout, palliative care, and alcohol use disorder (via the KARE protocol under partnership with Awakn Life Sciences). Services are delivered across three physical clinic locations in Manhattan, Rockland County (NY), and Aventura (FL), with psychiatric intake, continuous medical monitoring, preparation sessions, six-session IV ketamine protocols over three to six weeks, and bi-weekly integration circles forming the standard treatment arc.
Is Nushama a public or private company?
Nushama is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Nushama founded?
Nushama was founded in 2021. It employs 11 to 50 people.
Where is Nushama based?
Nushama is headquartered in New York, United States, in the North America region.
How does Nushama make money?
Five revenue lines are on record. IV Ketamine Infusions are the primary driver. The others are spravato (Esketamine) Treatment, one-Day TMS, NAD+ and Niagen Therapy and careCredit Financing.
Who are Nushama's main competitors?
Broad incumbents on record are Spravato (Janssen / Johnson & Johnson) and Compass Pathways. Restore Hyper Wellness is listed as a regional player. Direct peers are Field Trip Health, Mindbloom, Better U (formerly known as Keta Medical Center), Ketamine Clinics of Los Angeles (KCLA) and Actify Neurotherapies. Awakn Life Sciences is listed as an others. Innerwell is listed as an emerging player.
Does Nushama have an API?
No public API is recorded for Nushama.
What industry is Nushama in?
Nushama's product category is Ketamine Therapy Clinics. Its primary akta.pro industry code is EDALAFAB, Mental Health Counseling & Psychotherapy Services, with a secondary code of BPAGAEAO, Substance Use Recovery & Harm Reduction Support Services. Its NAICS code is 621420 and its SIC code is 8093.